To retrospectively analyze the effects of different doses of rivaroxaban on renal function outcome and prognosis in elderly patients with atrial fibrillation (AF) combined with stable coronary artery disease (SCAD).
A total of 416 elderly (≥65 years old) AF-SCAD patients who received rivaroxaban treatment (≥3 months) in our hospital from January to December 2018 were retrospectively analyzed, and divided into low-dose group (<10 mg/d), conventional-dose group (10 - 15 mg/d) and high-dose group (20 mg/d) according to the initial dose. The primary effective end points of treatment included cardiovascular death, myocardial infarction, ischemic stroke/transient ischemic attack, pulmonary embolism and deep venous thrombosis of the lower extremities. The primary safety end points were bleeding events and acute kidney disease (AKD).
There were statistically significant differences in baseline creatinine clearance and medication time of rivaroxaban among the three groups (P<0.05). The incidence of AKD in the high-dose group was higher than that in the low-dose group during follow-up (P<0.05). Univariate and multivariate logistic regression analysis showed that after adjusting the time of administration of rivaroxaban and the initial serum creatinine clearance, rivaroxaban 20 mg/d was still an independent risk factor for AKD in patients with AF-SCAD (odds rate=3.579, 95% confidence interval: 1.879 -9.974), and also the independent risk factor for AKD in patients with baseline serum creatinine clearance of 50 - 79ml/min or ≥80ml/min (odds rate=6.876, 95% confidence interval: 2.647 - 14.652, odds rate=2.159, 95% confidence interval: 1.042 - 5.477). In addition, for patients with baseline serum creatinine clearance of 50 - 79ml/min, the conventional dose of rivaroxaban (10 - 15 mg/d) also increase the risk of AKD in patients with AF-SCAD (odds rate=1.254, 95% confidence interval: 1.001 - 1.959).
Rivaroxaban 20 mg/d can increases AKD risk in elderly patients with AF-SCAD and received percutaneous coronary intervention.
| 科 Family | 属数 Number of genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) | 属 Genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) |
|---|---|---|---|---|---|---|
| 鹅膏菌科Amanitaceae | 2 | 11 | 5.26 | 鹅膏菌属 Amanita | 10 | 4.78 |
| 小菇科 Mycenaceae | 2 | 12 | 5.74 | 丝盖伞属 Inocybe | 5 | 2.39 |
| 多孔菌科 Polyporaceae | 8 | 14 | 6.70 | 蜡蘑属 Laccaria | 5 | 2.39 |
| 红菇科 Russulaceae | 3 | 23 | 11.00 | 小皮伞属 Marasmius | 6 | 2.87 |
| 小菇属 Mycena | 11 | 5.26 | ||||
| 光柄菇属 Pluteus | 5 | 2.39 | ||||
| 红菇属 Russula | 17 | 8.13 | ||||
| 栓菌属 Trametes | 5 | 2.39 |